JPRN-jRCT2031210131进行中（未招募）3 期
An open label, multi-center roll-over study to assess longterm safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment
Suzuki Kazuyuki0 个研究点目标入组 2 人开始时间: 2021年6月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Patient is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis or former GSK sponsored study which has fulfilled the requirements for the primary objective.
- •In the opinion of the Investigator would benefit from continued treatment.
排除标准
- •Patient has been previously permanently discontinued from study treatment in the parent protocol.
- •Patient's indication is commercially available and reimbursed in the local country.
- •Patient currently has unresolved toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study.
研究者
相似试验
进行中（未招募）
1 期
This clinical study is designed to provide continued access to pediatric patients who have previously participated in a dabrafenib and/or trametinib study and who in the opinion of the Investigator, would benefit from continued treatmentEUCTR2018-004459-19-NLovartis Pharma AG250
尚未招募
4 期
An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)NL-OMON51275ovartis3
招募中
4 期
An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatmentvarious rare malignant tumors10027655NL-OMON51217ovartis3
进行中（未招募）
1 期
This clinical study is designed to provide continued access to pediatric patients who have previously participated in a dabrafenib and/or trametinib study and who in the opinion of the Investigator, would benefit from continued treatmentChildren and Adolescents with Cancers Harboring V600 mutationsEUCTR2018-004459-19-DEovartis Pharma AG250
进行中（未招募）
1 期
This clinical study is designed to provide continued access to patients who have previously participated in a dabrafenib and/or trametinib study and who in the opinion of the Investigator, would benefit from continued treatmentPatients with BRAF V600 mutation positiveMedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001987-39-NLovartis Pharma AG78